FAQ on Lantern Pharma Inc.'s Completion of Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial

What is the LP-300 Phase 2 HARMONIC(TM) trial about?

The LP-300 Phase 2 HARMONIC(TM) trial is evaluating the investigational drug candidate LP-300 in never-smoker non-small cell lung cancer (NSCLC) patients, particularly those who have relapsed after tyrosine kinase inhibitor therapy, alongside standard chemotherapy agents.

Why is Japan a strategic region for this trial?

Japan has a high incidence of never-smoker NSCLC cases, making it a strategic region for the trial to address this under-addressed patient group with limited treatment options.

How does Lantern Pharma’s approach differ in this trial?

Lantern Pharma utilizes an AI-driven approach to identify and accelerate the development of therapies for underserved cancer markets, as demonstrated in the HARMONIC(TM) trial.

When is additional trial data expected?

Additional trial data from Taiwan and the U.S. is expected later in Q3 2025.

Where can I find more information about Lantern Pharma Inc.?

More information about Lantern Pharma Inc. (NASDAQ: LTRN) is available in the company’s newsroom at https://ibn.fm/LTRN.

What are the implications of completing enrollment ahead of schedule?

Completing enrollment ahead of schedule underscores Lantern Pharma’s efficiency and commitment to addressing the needs of never-smoker NSCLC patients, potentially accelerating the development of LP-300.

Who is involved in the HARMONIC(TM) trial?

The trial involves never-smoker NSCLC patients, particularly those who have relapsed after tyrosine kinase inhibitor therapy, and is conducted across five sites in Japan, including the National Cancer Center in Tokyo.

How can investors stay updated on Lantern Pharma Inc.?

Investors can stay updated on the latest news and updates relating to LTRN in the company’s newsroom at https://ibn.fm/LTRN.